Exelixis

Press Release

Exelixis

Press Release

Exelixis Announces June 1 Webcast of Its ASCO Investor and Analyst Briefing

May 15, 2009
PDF Version

Seven Abstracts Accepted for Presentation at ASCO

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May. 15, 2009-- Exelixis, Inc. (Nasdaq: EXEL) announced today that it will hold an investor and analyst briefing in conjunction with the American Society of Clinical Oncology (ASCO) Annual Meeting from 6:30 p.m. to 8:00 p.m. EDT on Monday, June 1, 2009. The event will be webcast and may be accessed in the Event Calendar page under Investors at http://www.exelixis.com.

An archived replay of this webcast will be available until 9:00 p.m. PDT/12:00 a.m. EDT on July 1, 2009. Access numbers for this replay are: 1-888- 286-8010 (domestic) and +1-617-801-6888 (international); the replay passcode is: 71489428.

Participants:

-- George A. Scangos, PhD, President and Chief Executive Officer
-- Michael M. Morrissey, PhD, President of Research and Development
-- Gisela M. Schwab, MD, Executive Vice President and Chief Medical Officer

Topics:

Data from ASCO and the Exelixis pipeline.

Abstracts to be presented at ASCO:

 
ASCO

Abstract

Number

  ASCO Abstract Title   Presentation Date and Time (EDT)
3512   A Phase 1 study of XL228, a potent IGF1R / AURORA / SRC inhibitor, in patients with solid tumors or hematologic malignancies   Saturday, May 30

4:15 p.m.

3513   A Phase 1 study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors   Saturday, May 30

4:30 p.m.

2047   A Phase 2 study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse   Sunday, May 31

8 a.m.-noon

2048   Use of neurovascular imaging in GBM patients (pts) to quantify early physiologic changes after treatment with XL184, an inhibitor of multiple receptor tyrosine kinases: results from a Phase 2 study   Sunday, May 31

8 a.m.-noon

2049   Correlative tumor molecular profiling and plasma biomarker analysis in a Phase 2 study of XL184 in patients with progressive or recurrent glioblastoma multiforme (GBM)   Sunday, May 31

8 a.m.-noon

3500   Phase 1 dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors   Monday, June 1

1:30 p.m.

3502   A Phase 1 dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors   Monday, June 1

2:00 p.m.

Exelixis is co-developing XL184 with Bristol-Myers Squibb Company and has out-licensed XL281 to Bristol-Myers Squibb Company for further development, but continues to conduct the ongoing phase 1 trials.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis’ broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, GlaxoSmithKline, Genentech, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information, please visit the company’s web site at www.exelixis.com.

Exelixis and the Exelixis logo are registered U.S. trademarks.

Source: Exelixis, Inc.

Exelixis, Inc.
Investor Contact:
Charles Butler, 650-837-7277
Executive Director, Corporate Communications
cbutler@exelixis.com
Media Contact:
Soleil Maxwell Harrison, 650-837-7012
Senior Manager, Corporate Communications
sharrison@exelixis.com

Shareholder Tools

Information Request Print Page RSS